Immunogenicity, efficacy, and safety of biosimilar insulin glargine (Gan & Lee glargine) compared with originator insulin glargine (Lantus®) in patients with type 2 diabetes after 26 weeks' treatment: A randomized open label study.

Elena A ChristofidesOrlando PuentePaul NorwoodDouglas DenhamHiralal MaheshwariMichael LillestolTerence HartSamer NakhleAnurekha ChadhaDavid Fitz-PatrickDanny H SugimotoJoseph SouferDouglas YoungMark L WarrenDavid HuffmanJohn ReedHarold BaysSamir AroraBarbara RizzardiRaymond TidmanMarc RendellKimball A Johnson

Published in: Diabetes, obesity & metabolism (2024)

GL Glargine was similar to Lantus® in terms of immunogenicity, efficacy, and safety, based on the current study.

Keyphrases

glycemic control
type diabetes
open label
clinical trial
squamous cell carcinoma
metabolic syndrome
radiation therapy
adipose tissue
phase ii
smoking cessation
rectal cancer